Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Reduced by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. lessened its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 58.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,155 shares of the biotechnology company’s stock after selling 8,576 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Arrowhead Pharmaceuticals were worth $417,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the company. iSAM Funds UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $29,000. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $32,000. WPG Advisers LLC lifted its position in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 431 shares during the last quarter. Federated Hermes Inc. bought a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at about $52,000. Finally, Smartleaf Asset Management LLC lifted its position in Arrowhead Pharmaceuticals by 2,186.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,618 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider directly owned 226,958 shares in the company, valued at $17,021,850. The trade was a 4.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer owned 162,905 shares in the company, valued at $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 33,095 shares of company stock worth $2,326,228 over the last quarter. Insiders own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

ARWR has been the topic of several recent research reports. B. Riley Financial lifted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, May 6th. Sanford C. Bernstein boosted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. assumed coverage on Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an “overweight” rating and a $88.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.80.

Arrowhead Pharmaceuticals Stock Down 1.5%

ARWR opened at $77.88 on Thursday. Arrowhead Pharmaceuticals, Inc. has a one year low of $14.30 and a one year high of $80.67. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The stock’s fifty day moving average is $65.40 and its 200-day moving average is $61.45. The company has a market capitalization of $10.97 billion, a PE ratio of -36.22 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company had revenue of $73.74 million for the quarter, compared to the consensus estimate of $73.84 million. During the same quarter in the previous year, the business earned $2.75 EPS. The company’s quarterly revenue was down 86.4% compared to the same quarter last year. On average, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.98 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.